ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6085
-0.43%
Brent Oil
83.76
0.67%
Bitcoin
66,896.74
2.54%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Fate Therapeutics Inc (FATE)

  7. Fate Therapeutics Inc (FATE) Noticias

FATE

Fate Therapeutics (FATE)

Fate Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:FATE
FechaHoraFuenteTítuloSímboloCompañía
09/05/202415:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
09/05/202415:01GlobeNewswire Inc.Fate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
09/05/202407:30GlobeNewswire Inc.Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramNASDAQ:FATEFate Therapeutics Inc
06/05/202407:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:FATEFate Therapeutics Inc
03/05/202415:30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
22/04/202415:30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
03/04/202407:00GlobeNewswire Inc.Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
02/04/202415:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
19/03/202407:44GlobeNewswire Inc.Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementNASDAQ:FATEFate Therapeutics Inc
05/03/202415:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
04/03/202412:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FATEFate Therapeutics Inc
01/03/202407:00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
26/02/202415:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FATEFate Therapeutics Inc
26/02/202415:01GlobeNewswire Inc.Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
15/02/202407:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
12/02/202417:06Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FATEFate Therapeutics Inc
02/02/202415:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
08/01/202407:00GlobeNewswire Inc.Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid TumorsNASDAQ:FATEFate Therapeutics Inc
13/12/202316:00GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
27/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FATEFate Therapeutics Inc
08/11/202315:44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:FATEFate Therapeutics Inc
08/11/202315:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FATEFate Therapeutics Inc
08/11/202315:01GlobeNewswire Inc.Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
25/10/202307:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
31/08/202307:00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
08/08/202315:01GlobeNewswire Inc.Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
28/07/202307:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
15/06/202315:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FATEFate Therapeutics Inc
08/06/202315:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FATEFate Therapeutics Inc
31/05/202307:00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming June Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FATE

Su Consulta Reciente

ASX
JHXCD
James Hardie Industries
NASDAQ
BRACU
Broad Capital Acquisition
COIN
USDLUSD
United States Dollar
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados